WHO-GMP Certified Commercial Pack · Product Code: AKP-009-LIQ
α-β Arteether Injection 150 mg / 2 ml
Formulation Overview: Semi-synthetic ethyl-ether artemisinin derivative (150 mg / 2 ml) formulated in sterile oily vehicle for sustained 24-hour once-daily intramuscular eradication of cerebral malaria parasites. Formulated with α-β Arteether 150 mg / 2 ml (150 mg / 2 ml) in Sterile Intramuscular Liquid Injection Ampoule dosage form under Antimalarials Medication, manufactured to IP / BP / USP Compendial standards and supplied in 3 x 2 ml Amber / Clear USP Type I Glass Ampoules with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-009-LIQ |
|---|---|
| Catalog Reference | AKP-009-LIQ · SN 9-Liq |
| Therapeutic Sector | Antimalarials Medication |
| Dosage Form | Sterile Intramuscular Liquid Injection Ampoule |
| Active Ingredient | α-β Arteether 150 mg / 2 ml |
| Strength / Purity | 150 mg / 2 ml |
| Clinical Indication | Severe and cerebral P. falciparum malaria and chloroquine-resistant vivax/falciparum co-infections |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 3 x 2 ml Amber / Clear USP Type I Glass Ampoules |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C, protect from light & do not freeze |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |